<DOC>
	<DOCNO>NCT02283983</DOCNO>
	<brief_summary>For specific patient population study receive 5-Fluorouracil , epirubicin cyclophosphamide - Docetaxel sequence ( cumulative dose &lt; 300 mg / m2 ) , use cryoprotection never assess . The effectiveness cryoprotection onycholysis secondary Docetaxel well establish population ( breast cancer adjuvant set ) base solely publication ( Scotté ) contain therapeutic modality ( dose significantly high ) . The study available heterogeneous population , nonrandomized , retrospective small sample . By extension observe higher cumulative dos docetaxel , team offer mittens booty chill patient , practice subject national consensus . The investigator wish accurately assess effectiveness mitten slipper chill , tolerance observance weak data specific population literature .</brief_summary>
	<brief_title>Evaluation Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>upper age 18 year mammary adenocarcinoma nonmetastatic histologically proven wait adjuvant neoadjuvant chemotherapy accord follow conventional scheme : 3 cycle F5Fluorouracil , epirubicin cyclophosphamide 100 ( 500 5Fluorouracil 600 mg / m² J1 , Epirubicin 100 mg / m² J1 , Cyclophosphamide 500 600 mg / m² J1 3 cycle Epiribucin Cyclophosphamide 100 ) follow 3 cycle docetaxel , 100 mg / m² , +/ trastuzumab Her2+++ Patient capacity/faculties understand newsletter sign inform consent Patient receive social coverage Patient treat follow center period least one year WHO scale 0 1 Age 18 year Diseases scalp whatever hairshowing helmet alopecia Using pre nail resin per chemotherapy mammary adenocarcinoma stage IV Indication docetaxel cancer another organ breast Treatment processing program chemotherapy innovative molecule evaluate Raynaud 's syndrome , cold agglutinin disease , cryoglobulinemia cryofibrinogenemia . Uncontrolled severe arterial disease . Presence device &gt; grade 1 neuropathy start chemotherapy Patient unable submit protocol follow psychological , social , family geographical Patient incompatible underlying disease concomitant inclusion trial , whether psychiatric somatic Patient trust , guardianship , legal protection measure , deprive freedom Male Criteria non randomization ( first course docetaxel ) : Presence peripheral neuropathy &gt; grade 1 first 3 cycle 5Fluorouracil , epirubicin cyclophosphamide 100 . Presence nail skin toxicity &gt; grade 1 3 cycle 5Fluorouracil , epirubicin cyclophosphamide 100 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>